CLYM

Climb Bio, Inc.

Healthcare · Biotechnology

$129.24 sample

+1.92 (+1.51%) 1D

Market cap

$376.0B

Price as of

2026-10-15

Latest filing

8-K · 2026-09-03

Alerts

8

Price$129.24 +15.61% 3M daily closessample

137.44111.79

2026-07-202026-08-112026-09-022026-09-232026-10-15

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 07INSInsider buy: EVP, Operations
Oct 01INSInsider sell: Chief Executive Officer
Sep 28INSInsider buy: 10% owner
Sep 21INSInsider buy: Chief Executive Officer
Sep 14INSInsider sell: Chief Financial Officer
Sep 03SECForm 144 filed
Aug 27SECDEF 14A filed
Aug 24INSInsider sell: EVP, Operations

Sign up to see the real CLYM record →

Company facts

SEC EDGAR registration

Name: Climb Bio, Inc.
Sector: Healthcare
Industry: Biotechnology
Smart-money score: -5sample, -100 to +100
Reporting currency: USD

Who is positioning in CLYM

sample

Insiders: 33 insider transactions over 90 days, net selling, $226.4M
Congress: 4 members traded over 90 days
Institutions · 13F: 13 funds hold $7.5B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$15.6B +17.2% y/y

Q4 2024Q3 2026

Inventory$9.1B +3.8% y/y

Q4 2024Q3 2026

Accounts receivable$7.1B +17.9% y/y

Q4 2024Q3 2026

Total debt$18.6B +9.8% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $357.9B +6.2% 3M
Sample peer B: $303.6B -3.2% 3M
Sample peer C: $238.9B +1.0% 3M
Sample peer D: $50.0B +15.1% 3M
Sample peer E: $206.4B +9.0% 3M